lenalidomide + prednisone

lenalidomide + prednisone is a combination therapy evaluated by the M.D. Anderson Cancer Center for the treatment of myelofibrosis. Lenalidomide is a small molecule immunomodulatory drug (IMiD) that binds to the cereblon E3 ubiquitin ligase complex, leading to the degradation of transcription factors and inhibition of proinflammatory cytokines like TNF-alpha. Prednisone is a corticosteroid that acts as a glucocorticoid receptor agonist, providing anti-inflammatory effects and potentially reducing bone marrow fibrosis. In Phase 2 clinical trials conducted at M.D. Anderson, this combination demonstrated efficacy in improving anemia and reducing splenomegaly in patients with myelofibrosis, with some patients achieving durable responses lasting over five years. The regimen typically involves cyclic administration of lenalidomide alongside a tapering dose of prednisone to optimize hematologic improvement and manage side effects.

Brand names

Revlimid

Other names

lenalidomide and prednisoneCC-5013 and prednisoneCC5013 and prednisoneCC 5013 and prednisone